Vivacta’s cartridges incorporate an innovative piezofilm sensor. The company’s technology platform allows the development of next-generation point-of-care diagnostics and monitoring systems.
The company is applying its expertise in piezofilm technology to develop a variety of new generation high performance PoC diagnostics able to deliver quantitative readings within 10 minutes from a single pin prick of blood.
The finger-prick tests provide lab-quality measurement of disease markers and drugs in whole-blood in under 10 minutes, claims the company.
Vivacta CEO Tim Carter said the formation of the pilot facility in 2009 gave Vivacta the strategic advantage of being able to develop new tests on consistently manufactured materials and demonstrated to potential commercial partners the scaleability of their process.
The company has appointed Andrew Whittle as process engineering manager to lead the initiative.
